期刊文献+

嗜中性活性肽2(NAP-2)在人肝癌细胞株和肝癌组织的表达 被引量:1

Expressions of NAP-2 protein in human hepatoma cell line SMCC-7721 and hepatocellular carcinoma tissues
下载PDF
导出
摘要 目的:探讨NAP-2在人肝癌细胞株SMCC-7721和人肝正常细胞株HL-7702、肝癌组织及其癌旁组织表达的差异性。方法:采用免疫细胞化学法(Immunocytochemistry,ICC)检测人肝癌细胞株SMCC-7721和人肝正常细胞株HL-7702中NAP-2蛋白的表达,免疫组织化学法(Immunohistochemistry,IHC)检测30例肝癌组织及其癌旁组织中NAP-2蛋白的表达。结果:NAP-2在人肝癌细胞株SMCC-7721表达率为100%,人肝正常细胞株HL-7702无表达。在肝癌组织中强阳性表达率为63.33%,癌旁组织无强阳性表达;经统计学分析,两者NAP-2的表达呈显著差异(P<0.01)。结论:NAP-2在肝癌发生、发展过程中可能起着一定作用。 Objective: To detect and analyze the expression of NAP - 2 in SMCC - 7721 and HL - 7702, hepatocellular carcinoma and its adjacent tissues. Methods:Immunocytochemical staining and immunohistochemical method were used to detect expressions of NAP -2 protein in SMCC -7721 and HL -7702,30 hepatocellular carcinoma tissues and their adjacent tissues ,respectively. Results:In SMCC -7721, the NAP -2 protein positive rates was 100%, there was no NAP - 2 protein expression in HL - 7702. In 30 hepatocellular carcinoma tissues, NAP - 2 protein strong positive rate was 63.33 % , but no strong expression in HCC adjacent tissues (P 〈 0.01 ). Conclusion:NAP -2 protein may be related with the occurrence, development and progress of hepatocellular carcinoma.
出处 《现代肿瘤医学》 CAS 2009年第6期1122-1124,共3页 Journal of Modern Oncology
基金 广西科学基金项目(桂科能05112001-4A 桂科能0630006-5E 桂科攻0592007-1C)
关键词 肝癌 嗜中性活性肽-2 免疫细胞化学 免疫组织化学 hepatocellular carcinoma NAP - 2 ICC IHC
  • 相关文献

参考文献8

  • 1Balkwill F.Chemokine biology in cancer[J].Semin Immunol,2003,15(1):49-55.
  • 2Min H,Jian Q,Rihong Z,et al.Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach[J].Proteome Sci,2008,6(1):10.
  • 3Shin EC,Choi YH,Kim JS,et al.Expression patterns of cytokines and Chemokines genes in human hepatoma cells[J].Yonsei Med J,2002,43(5):657-664.
  • 4Akiba J,Yano H,Ogasawara S,et al.Expression and function of interleukin-8 in human hepatocellular carcinoma[J].Int J Oncol,2001,18(2):257-264.
  • 5Nakazakjh.Perperative and postoperative cytokines in patients with cancer[J].Cancer,1992,70:709.
  • 6Homey B,Muller A,Zlotnik A.Chemokines:agents for the immunotherapy of cancer[J].Nat Rev Immunol,2002,2(3):175-184.
  • 7Lentsch AB.The Duffy antigen/receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white[J]? FASEB J,2002,16(9):1093-1095.
  • 8Belperio JA,Keane MP,Aranberg DA,et al.CXC chemokines in angiogenesis[J].J Leukoc Biol,2000,68(1):1-8.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部